LynchVax reaches a major milestone: first UK preventive vaccine trial approved
- 11 hours ago
- 3 min read
MHRA approval marks an important step forward for Lynch syndrome cancer prevention research
There is exciting news from the Oxford LynchVax team. After years of laboratory research, patient involvement and careful planning, the first UK clinical trial of a preventive vaccine designed specifically for people with Lynch syndrome has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA).
For many in our community, this is a milestone that once felt a long way off. While there is still much work to do before any vaccine could become widely available, this approval means LynchVax is moving from the laboratory into human clinical trials for the first time in the UK.
What is LynchVax?
As we've shared in previous updates, LynchVax is a research programme led by Professor David Church and colleagues at the University of Oxford that aims to develop a vaccine capable of preventing cancers associated with Lynch syndrome.
The newly approved study, called INTERCEPT-Lynch, will investigate an mRNA vaccine known as mRNA-4194. The vaccine has been designed to help the immune system recognise and respond to abnormal cells associated with Lynch syndrome before cancer develops.
The project is sponsored by the University of Oxford and funded by Moderna, whose expertise in mRNA vaccine development has helped accelerate progress.
Why this matters
People with Lynch syndrome face an increased lifetime risk of several cancers, including bowel, endometrial, ovarian, stomach and other cancers.
Current prevention relies heavily on surveillance, screening, risk-reducing surgery where appropriate, and measures such as aspirin therapy. A vaccine that could train the immune system to identify and eliminate pre-cancerous cells would represent an entirely new approach to cancer prevention.
Importantly, the trial does not mean that a preventive vaccine has been proven to work. Rather, it marks the start of the process needed to answer that question safely and rigorously.
What happens next?
The first participants are expected to begin treatment during summer 2026.
However, recruitment is not yet open. The initial Phase 1 stage will involve fewer than 24 participants and is expected to be completed within approximately one year. Participants must have a confirmed diagnosis of Lynch syndrome and must not have had a cancer diagnosis within the previous three years.
Because the study is small and time-sensitive, the research team expects to prioritise people living locally to the trial centre whose medical records can be accessed more easily. Eligible individuals may be contacted directly by their clinical teams.
The good news is that a second phase, expected to begin during the first half of 2027, aims to recruit between 80 and 110 participants from multiple hospitals across the UK.
Understanding early-phase clinical trials
The LynchVax team has been careful to explain what participation in an early-phase study means.
Phase 1 and Phase 2 trials are designed primarily to establish safety, determine appropriate dosing and assess whether the vaccine generates the expected immune response. They are not designed to prove cancer prevention.
There are potential benefits to taking part, including contributing to research that could help future generations of people with Lynch syndrome. However, because the treatment is being tested in people for the first time, not all side effects may be known, and participants may receive lower doses than those eventually used in later studies.
If the first two phases demonstrate that the vaccine is safe and performs as expected, larger studies involving hundreds or potentially thousands of participants would typically follow.
A moment worth celebrating
At Lynch Syndrome UK, we are proud to have supported the LynchVax team in engaging with the Lynch community over recent years. We know how much hope this research has generated, and we are grateful to the research team, funders and everyone in our Lynch community who has shared their experiences, attended events, completed surveys and contributed samples that have helped make this progress possible.
This approval is not the finish line. But it is an important and tangible step towards a future where preventing Lynch-associated cancers may become increasingly possible.
We will continue to share updates as the research progresses and as further recruitment opportunities become available.
If you missed Dr David Church's latest update at the Lynch Syndrome UK Conference 2026, keep an eye on our channels as recordings will be available soon. In the meantime, you can watch his previous conference presentation on our YouTube channel.
If you'd like to receive updates, sign up to receive the LynchVax quarterly newsletter by emailing Sara Danielli: sara.danielli@medsci.ox.ac.uk, or find out more on the LynchVax website: LynchVax — Oxford Cancer
Sources: LynchVax Newsletter (Issue 5 - June 2026):